Free Trial

Petros Pharmaceuticals (PTPI) Competitors

Petros Pharmaceuticals logo
$0.03 0.00 (-8.88%)
As of 07/7/2025 03:58 PM Eastern

PTPI vs. INM, TTNP, PLRZ, EVOK, LIPO, DRMA, VIVS, CMND, CANF, and ARTL

Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include InMed Pharmaceuticals (INM), Titan Pharmaceuticals (TTNP), Polyrizon (PLRZ), Evoke Pharma (EVOK), Lipella Pharmaceuticals (LIPO), Dermata Therapeutics (DRMA), VivoSim Labs (VIVS), Clearmind Medicine (CMND), Can-Fite BioPharma (CANF), and Artelo Biosciences (ARTL). These companies are all part of the "pharmaceutical products" industry.

Petros Pharmaceuticals vs. Its Competitors

Petros Pharmaceuticals (NASDAQ:PTPI) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

InMed Pharmaceuticals has lower revenue, but higher earnings than Petros Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.19-$8.16M-$119.000.00
InMed Pharmaceuticals$4.60M0.72-$7.68M-$12.09-0.23

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Petros Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. Petros Pharmaceuticals' return on equity of -78.22% beat InMed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
InMed Pharmaceuticals -168.87%-107.93%-82.97%

Petros Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.

In the previous week, InMed Pharmaceuticals had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for InMed Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.32 beat Petros Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
InMed Pharmaceuticals Neutral

Summary

Petros Pharmaceuticals beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTPI vs. The Competition

MetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$991K$784.82M$5.52B$9.02B
Dividend YieldN/A4.84%5.24%4.05%
P/E Ratio-0.011.3027.2520.08
Price / Sales0.19230.49371.3293.25
Price / CashN/A23.4426.2128.59
Price / Book0.016.237.945.55
Net Income-$8.16M-$27.94M$3.17B$248.49M
7 Day PerformanceN/A2.40%1.79%4.87%
1 Month PerformanceN/A8.93%1.27%6.63%
1 Year PerformanceN/A8.65%33.57%20.38%

Petros Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTPI
Petros Pharmaceuticals
0.644 of 5 stars
$0.03
-8.9%
N/A-99.7%$991K$5.11M-0.0120Gap Down
INM
InMed Pharmaceuticals
1.0271 of 5 stars
$3.25
-3.8%
N/A-48.1%$4.08M$4.60M-0.2710Analyst Upgrade
Gap Down
TTNP
Titan Pharmaceuticals
0.093 of 5 stars
$4.20
-4.5%
N/A-13.6%$4.02M$180K-0.9210Gap Down
PLRZ
Polyrizon
N/A$0.74
0.0%
N/AN/A$3.94MN/A0.00N/APositive News
Gap Down
EVOK
Evoke Pharma
N/A$2.60
-1.1%
N/A-59.1%$3.92M$10.25M-0.914Positive News
LIPO
Lipella Pharmaceuticals
1.3047 of 5 stars
$0.87
-3.6%
N/A-76.9%$3.88M$536.36K-0.214
DRMA
Dermata Therapeutics
1.4665 of 5 stars
$0.59
-3.2%
$3.00
+412.8%
-70.6%$3.85MN/A-0.048News Coverage
VIVS
VivoSim Labs
N/A$1.47
flat
N/AN/A$3.82M$140K-0.1420Positive News
CMND
Clearmind Medicine
0.6275 of 5 stars
$0.90
+1.2%
N/A-38.0%$3.79MN/A-0.82N/A
CANF
Can-Fite BioPharma
3.282 of 5 stars
$1.05
+1.0%
$14.00
+1,233.3%
-57.9%$3.72M$674K-0.598
ARTL
Artelo Biosciences
2.9624 of 5 stars
$13.27
+95.4%
$33.00
+148.7%
+78.8%$3.71MN/A-0.745News Coverage
Analyst Upgrade
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:PTPI) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners